ERBB2 and breast carcinoma: AKT mutations are less commonly reported in breast cancer, with less common AKT substitutions (2–4%) or amplifications (5–10%) present.[91] The PH domain of AKT1 is where the predominant AKT mutation in HER2-positive breast cancer commonly takes place.